| Bayesian clinical decision support-guided versus clinician-guided vancomycin dosing in attainment of targeted pharmacokinetic parameters in a paediatric population DM Hughes, S Goswami, RJ Keizer, MSA Hughes, JD Faldasz Journal of Antimicrobial Chemotherapy 75 (2), 434-437, 2020 | 27 | 2020 |
| A review of novel agents and clinical considerations in patients with ATTR cardiac amyloidosis M Benbrahim, K Norman, V Sanchorawala, OK Siddiqi, D Hughes Journal of Cardiovascular Pharmacology 77 (5), 544-548, 2021 | 19 | 2021 |
| Review of the long-term effects of proton pump inhibitors LWB Lehault, DM Hughes Federal Practitioner 34 (2), 19, 2017 | 15 | 2017 |
| Bortezomib ocular toxicities: Outcomes with ketotifen. M Dennis, A Maoz, D Hughes, V Sanchorawala, JM Sloan, S Sarosiek American Journal of Hematology 94 (3), E80-E82, 2019 | 11 | 2019 |
| Transitioning from thrombopoietin agonists to the novel SYK inhibitor fostamatinib: a multicenter, real-world case series DM Hughes, C Toste, C Nelson, J Escalon, F Blevins, B Shah Journal of the Advanced Practitioner in Oncology 12 (5), 508, 2021 | 9 | 2021 |
| Droxidopa for treatment of refractory orthostatic hypotension in patients with AL amyloidosis: A case series JNR Lopez, LM Mendelson, T Joshi, D Hughes, MC Kaku, ... Blood 138, 4737, 2021 | 6 | 2021 |
| Fatal hepatitis B reactivation in a patient receiving chemoradiation for cervical cancer C Dimond, A Negroiu, D M. Hughes, J Patel Journal of Oncology Pharmacy Practice 27 (5), 1296-1301, 2021 | 6 | 2021 |
| OPTIMAL breast cancer care: Effect of an outpatient pharmacy team to improve management and adherence to oral cancer treatment JV Patel, DM Hughes, NY Ko JCO Oncology Practice 19 (3), e306-e314, 2023 | 5 | 2023 |
| Pharmacist responsiveness and readiness for oral antivirals for COVID-19: a rebuttal to the AMA statement regarding the Biden administration’s test-to-treat plan DM Hughes, J Mordino Journal of the American Pharmacists Association 62 (4), 1162-1164, 2022 | 5 | 2022 |
| A pharmacist’s review of the treatment of systemic light chain amyloidosis DM Hughes, A Staron, V Sanchorawala Journal of Oncology Pharmacy Practice 27 (1), 187-198, 2021 | 5 | 2021 |
| Standard 30-minute monitoring time and less intensive pre-medications is safe in patients treated with subcutaneous daratumumab for multiple myeloma and light chain amyloidosis DM Hughes, L Henshaw, F Blevins, C Edwards, A Lerner, JM Sloan, ... Clinical Lymphoma Myeloma and Leukemia 22 (8), 566-568, 2022 | 3 | 2022 |
| Incidence of skin hyperpigmentation in Black patients receiving treatment with immunomodulatory drugs CJ Milrod, F Blevins, D Hughes, A Lerner, S Sarosiek, V Sanchorawala, ... Blood, The Journal of the American Society of Hematology 137 (21), 2987-2989, 2021 | 3 | 2021 |
| Safety, tolerability, and efficacy of selinexor in a patient with relapsed light chain (AL) amyloidosis DM Hughes, S DeMari, V Sanchorawala, JM Sloan Clinical Lymphoma, Myeloma and Leukemia, 2021 | 3 | 2021 |
| Pharmacist-Run Chemotherapy-Induced Nausea and Vomiting Management Protocol Improves Patient Outcomes and Benefits Physician Workflow. DM Hughes, RL Vose, B Shah, R Jhaveri Journal of Hematology Oncology Pharmacy 10 (4), 2020 | 3 | 2020 |
| Pharmacist-driven assessment and prescribing of COVID-19 therapeutics: A large, tertiary academic medical center’s experience DE Famularo, J Koloski, J Marathe, A Au, S Hamilton, J Mordino, ... American Journal of Health-System Pharmacy 79 (21), 1889-1893, 2022 | 2 | 2022 |
| Underrepresentation of Black participants and adverse events in clinical trials of lenalidomide for myeloma CJ Milrod, M Mann, F Blevins, D Hughes, P Patel, KY Li, A Lerner, ... Critical Reviews in Oncology/Hematology 172, 103644, 2022 | 2 | 2022 |
| Real-world experience with fostamatinib in patients with immune thrombocytopenia at an academic medical center D Hughes, F Blevins, B Shah, S Sarosiek, A Lerner, JM Sloan Blood 134, 4912, 2019 | 2 | 2019 |
| Risky business: Lessons from medication misadventures in chronic kidney disease C Gilmartin, AB Pai, D Hughes, N Hilal Physician Assistant Clinics 1 (1), 55-76, 2016 | 2 | 2016 |
| Successful conversion and implementation to subcutaneous daratumumab in patients with multiple myeloma (Mm) and light chain (Al) amyloidosis D Hughes, L Henshaw, F Blevins, CV Edwards, A Lerner, JM Sloan, ... Blood 138, 1975, 2021 | 1 | 2021 |
| Improvement in clinic efficiency, patient satisfaction, and overcoming unique challenges in the era of COVID-19 with implementation of subcutaneous daratumumab in patients with … D Hughes, R Jhaveri, B Shah, F Blevins, A Rodriguez, S Sarosiek, ... Blood 136, 42-43, 2020 | 1 | 2020 |